


ITJ

PATENT

Attorney Docket No. 5470-398



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Lentz et al.  
Application No.: 10/572,521  
Filed: March 21, 2006  
For: Soluble Phospholipids for Use in Clotting Factor Assays

Confirmation No.: 4732  
Group Art Unit: 1651

Date: July 28, 2006

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT  
PURSUANT TO 37 C.F.R. § 1.97(b)**

Sir:

Attached is a list of documents on Form PTO-1449, together with a copy of any listed foreign patent document and/or non-patent literature. A copy of any listed U.S. patent and/or U.S. patent application publication is not provided herewith in accordance with the amendment by the U.S. Patent and Trademark Office to 37 C.F.R. § 1.98(a)(2)(ii) effective October 21, 2004.

This Information Disclosure Statement is submitted in accordance with 37 C.F.R. § 1.97(b), within three months of the filing date of the above-referenced application or before the mailing of a first Office Action on the merits, whichever event occurs last. Therefore, no fee is believed due. However, the Commissioner is hereby authorized to charge any deficiency or credit any overpayment to Deposit Account No. 50-0220.

It is requested that these documents be considered by the Examiner and officially made of record in accordance with the provisions of 37 C.F.R. §1.56 and Section 609 of the MPEP.

Respectfully submitted,

*Karen A. Magri*  
Karen A. Magri  
Registration No. 41,965

Myers Bigel Sibley & Sajovec, P.A.  
P. O. Box 37428  
Raleigh, North Carolina 27627  
Telephone: (919) 854-1400  
Facsimile: (919) 854-1401  
Customer No. 20792

**CERTIFICATE OF EXPRESS MAIL**

Express Mail Label Number: EV 854924990 US  
Date of Deposit: July 28, 2006  
I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

*Katie Wu*  
Katie Wu

Substitute form 1449A/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	10/572,521
		Filing Date	March 21, 2006
		First Named Inventor	Lentz et al.
		Group Art Unit	1651
		Examiner Name	To be assigned
Sheet <b>A1</b>	of	Attorney Docket Number	5470-398

### U.S. PATENTS AND PATENT PUBLICATIONS

Examiner Initials*	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code (if known)		

### FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T
		Office	Number	Kind Code (if known)			

### OTHER NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T
	1	Banerjee et al., "Role of Procoagulant Lipids in Human Prothrombin Activation. 2. Soluble Phosphatidylserine Upregulates and Directs Factor X <sub>a</sub> to Appropriate Peptide Bonds in Prothrombin," <i>Biochemistry</i> , 2002, 41, pp. 950-957.	
	2	Banerjee et al., "Specificity of Soluble Phospholipid Binding Sites on Human Factor X <sub>a</sub> ," <i>Biochemistry</i> , 2002, 41, pp. 7751-7762.	
	3	Koppaka et al., "Soluble Phospholipids Enhance Factor X <sub>a</sub> -Catalyzed Prothrombin Activation in Solution," <i>Biochemistry</i> , 1996, 35(23), pp. 7482-7491.	
	4	Lentz, "Exposure of platelet membrane phosphatidylserine regulates blood coagulation," <i>Progress in Lipid Research</i> , 2003, 42, 423-438.	
	5	Lentz, Oral Presentation of "Phosphatidylserine (Not a Membrane Surface) is Required for Efficient Prothrombin Activation" XIX Congress of the International Society on Thrombosis and Haemostasis, Birmingham, United Kingdom, July 12-18, 2003.	
	6	Majumder et al., "Effects of Water Soluble Phosphatidylserine on Bovine Factor X <sub>a</sub> : Functional and Structural Changes Plus Dimerization," <i>Biophysical Journal</i> , 2003, 84, pp. 1238-1251.	
	7	Majumder et al., "Efficient human thrombin generation requires molecular phosphatidylserine and not a membrane surface," XIX Congress of the International Society on Thrombosis and Haemostasis, Meeting Abstracts, Birmingham, United Kingdom, July 12-18, 2003.	
	8	Majumder et al., "Soluble Phosphatidylserine Triggers Assembly in Solution of a Prothrombin-activating Complex in the Absence of a Membrane Surface," <i>The Journal of Biological Chemistry</i> , 2002, 277(33), pp. 29765-29773.	
	9	Morrissey et al., "Quantitation of Activated Factor VII Levels in Plasma Using a Tissue Factor Mutant Selectively Deficient in Promoting Factor VII Activation," <i>Blood</i> , 1993, 81(3), pp. 734-744.	
	10	Srivastava et al., "Localization of Phosphatidylserine Binding Sites to Structural Domains of Factor X <sub>a</sub> ," <i>The Journal of Biological Chemistry</i> , 2002, 277(3), pp. 1855-1863.	
	11	Srivastava et al., "Soluble Phosphatidylserine Binds to a Single Identified Site in the C2 Domain of Human Factor V <sub>a</sub> ," <i>Biochemistry</i> , 2001, 40(28), pp. 8246-8255.	
	12	Weinreb et al., "Cooperative Roles of Factor V <sub>a</sub> and Phosphatidylserine-containing Membranes as Cofactors in Prothrombin Activation," <i>The Journal of Biological Chemistry</i> , 2003, 278(8), pp. 5679-5684.	
	13	Zhai et al., "Phosphatidylserine Binding Alters the Conformation and Specifically Enhances the Cofactor Activity of Bovine Factor V <sub>a</sub> ," <i>Biochemistry</i> , 2002, 41, pp. 5675-5684.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.